Objectives: Myasthenia gravis (MG) is an autoimmune disorder in which antibodies interfere with neuromuscular transmission. Azathioprine (AZA) is an immunosuppressant frequently used for treatment of various autoimmune conditions, including MG. The literature suggests that the rates of AZA-associated hepatotoxicity and myelosuppression in MG are highly variable. Published studies have not formally analyzed their pattern, severity, timing, and/or recovery. We assessed the prevalence, pattern and timing of AZA associated toxicity in a large group of MG patients.
Methods: We identified 113 patients with MG with AZA-associated toxicity among 571 managed with this immunosuppressant. The timing of when toxicities occurred as well as pattern of laboratory abnormalities was assessed.
Results: The overall prevalence of hepatotoxicity and myelosuppression was 15.2% and 9.1%, respectively. The most common pattern of hepatotoxicity seen was gamma-glutamyl transpeptidase (GGT) enzyme elevation in 67.8% of patients. Of note, 21.2% of patients with myelosuppression had normocytic anemia, 17.3% had pancytopenia, and another 17.3% developed macrocytic anemia.
Conclusions: AZA-associated hepatotoxicity and myelosuppression in MG are not uncommon and may be underrecognized depending on the timing, frequency, and specific tests ordered for blood work monitoring.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CND.0000000000000133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prophylactic trimethoprim-sulfamethoxazole is safe in adult patients with primary central nervous system lymphoma receiving high-dose methotrexate.
Ann Hematol
December 2024
Department of Pharmacy, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai, 200040, China.
This retrospective study investigated the potential drug-drug interactions between trimethoprim-sulfamethoxazole (TMP-SMZ) and high-dose methotrexate (HD-MTX) in adult patients with primary central nervous system lymphoma (PCNSL). A total of 143 Chinese adult patients with PCNSL who received 498 cycles of MTX were included. Differences in the pharmacokinetics of MTX, including C, clearance (CL) and AUC with and without co-administration of TMP-SMZ were assessed.
View Article and Find Full Text PDFLung cancer, platinum analog-based frontline treatment and pharmacogenetic limitations.
Per Med
December 2024
Faculty of Biology, Kabul University, Afghanistan.
Article Synopsis
- - Lung cancer is the most lethal type of cancer worldwide, and the main treatment, cisplatin, often leads to rapid resistance and severe side effects like hearing loss and kidney damage.
- - This review focuses on the link between specific gene variations (single nucleotide polymorphisms or SNPs) and the toxicity caused by cisplatin.
- - The authors suggest using knowledge about these genetic variations to reduce the chances of treatment failure and minimize harmful side effects from cisplatin.
Synthesis, modification, characterization, and in vitro evaluation of chitosan-hyaluronic acid coated MIL-100 (Fe) nanoparticles for methotrexate delivery in rheumatoid arthritis.
Int J Biol Macromol
December 2024
Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address:
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain, swelling, and potential joint destruction. Effective management of RA is crucial to improve patients' quality of life and prevent long-term disability. Methotrexate (MTX) is a widely used disease-modifying antirheumatic drug (DMARD) that has shown efficacy in treating RA.
View Article and Find Full Text PDFIncidence, types and predictors of adverse events and their impact on treatment outcomes in multidrug/rifampicin resistant tuberculosis patients receiving all oral treatment regimens.
J Eval Clin Pract
November 2024
Association for Community Development, Khyber Pakhtunkhwa, Pakistan.
Background: Patients suffering from multidrug/rifampicin resistant tuberculosis (MDR/RR-TB) are treated for prolonged periods with a complex regimen comprised of relatively less effective and more toxic anti-TB drugs, consequently resulting in high incidence of adverse events (AEs).
Study Aim: The current study evaluates the incidence, types, management and predictors of AEs, and their impact on treatment outcomes in MDR/RR-TB patients receiving all oral treatment regimens.
Study Design: A total of 242 eligible MDR/RR-TB patients treated at two different study sites from June 2019 to December 2021 were included in this study.
Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database.
Expert Opin Drug Saf
October 2024
Department of Pharmacy, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- The study compared the safety profiles of four anti-herpesvirus drugs—acyclovir, ganciclovir, valaciclovir, and foscarnet—using data from the FDA Adverse Event Reporting System from 2004 to 2023.
- All drugs showed significant risks for hematotoxicity, with ganciclovir and foscarnet being the most myelosuppressive.
- Specific associations were noted: foscarnet posed the highest risk for renal impairment and seizures, while acyclovir had strong ties to neurotoxicity and severe skin reactions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!